Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 April 2020Big PharmaRory O'Neill

Gilead told to waive remdesivir patent rights

Almost 150 health and poverty activist campaigns, including  Médecins Sans Frontières, have urged  Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Americas
US govt doesn’t have remdesivir patent rights, says GAO
1 April 2021   The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Americas
US govt doesn’t have remdesivir patent rights, says GAO
1 April 2021   The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office.

More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Americas
US govt doesn’t have remdesivir patent rights, says GAO
1 April 2021   The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent